These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16273004)

  • 21. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer.
    Scagliotti GV; Selvaggi G
    Clin Lung Cancer; 2008; 9 Suppl 3():S122-8. PubMed ID: 19419926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-line treatment for advanced non-small cell lung cancer: how to design a clinical trial for a new agent?
    Paesmans M; Berghmans T; Sculier JP
    Lung Cancer; 2007 Feb; 55(2):135-6. PubMed ID: 17118490
    [No Abstract]   [Full Text] [Related]  

  • 23. Does maintenance pemetrexed maintain quality of life?
    Stinchcombe TE; Cella D
    Lancet Oncol; 2012 Mar; 13(3):224-5. PubMed ID: 22336220
    [No Abstract]   [Full Text] [Related]  

  • 24. Patients with advanced non-small-cell lung cancer and marginal performance status: walking the tight rope towards improved survival.
    West HJ
    J Clin Oncol; 2013 Aug; 31(23):2841-3. PubMed ID: 23835705
    [No Abstract]   [Full Text] [Related]  

  • 25. Activity of pemetrexed on brain metastases from non-small cell lung cancer: what is the mechanism?
    Dogan M; Yalcin B; Utkan G; Urun Y; Ozal G
    Lung Cancer; 2009 Dec; 66(3):399. PubMed ID: 19783320
    [No Abstract]   [Full Text] [Related]  

  • 26. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.
    Grønberg BH; Bremnes RM; Aasebø U; Brunsvig P; Fløtten O; Amundsen T; von Plessen C; Wang M; Sundstrøm S;
    Lung Cancer; 2009 Jan; 63(1):88-93. PubMed ID: 18538889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pneumocystis pneumonia in a patient with non-small cell lung cancer (NSCLC) treated with pemetrexed containing regimen.
    Velcheti V; Govindan R
    Lung Cancer; 2007 Aug; 57(2):240-2. PubMed ID: 17400329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multi-target tumor therapy].
    Krankenpfl J; 2005; 43(1-3):38-9. PubMed ID: 15912831
    [No Abstract]   [Full Text] [Related]  

  • 30. Pemetrexed as a single agent in the therapy of advanced lung cancer.
    Postmus PE; Bunn PA
    Semin Oncol; 2002 Apr; 29(2 Suppl 5):17-22. PubMed ID: 12023788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interstitial pneumonitis after treatment with pemetrexed: a rare event?
    Hochstrasser A; Benz G; Joerger M; Templeton A; Brutsche M; Früh M
    Chemotherapy; 2012; 58(1):84-8. PubMed ID: 22377772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management and maintenance of pemetrexed monotherapy regimen - initial experience of pretreated non-small cell lung cancer].
    Takase M; Maruoka H; Ametani F; Takahashi M; Shibata K
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):563-5. PubMed ID: 22504678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reality check for pemetrexed and maintenance therapy in advanced non-small-cell lung cancer.
    Murray N
    J Clin Oncol; 2014 Feb; 32(5):482-3. PubMed ID: 24395844
    [No Abstract]   [Full Text] [Related]  

  • 34. Pemetrexed for treatment of advanced non-small cell lung cancer.
    Fossella FV
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):100-5. PubMed ID: 14981587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.
    Ohe Y; Ichinose Y; Nakagawa K; Tamura T; Kubota K; Yamamoto N; Adachi S; Nambu Y; Fujimoto T; Nishiwaki Y; Saijo N; Fukuoka M
    Clin Cancer Res; 2008 Jul; 14(13):4206-12. PubMed ID: 18594001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
    Duruisseaux M; Cadranel J; Biron E; Pérol M; Guérin JC; Arpin D
    Lung Cancer; 2009 Sep; 65(3):385-7. PubMed ID: 19346028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimetabolites in the management of non-small cell lung cancer.
    Budde LS; Hanna NH
    Curr Treat Options Oncol; 2005 Jan; 6(1):83-93. PubMed ID: 15610718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report.
    Tiseo M; Gelsomino F; Bartolotti M; Barili MP; Ardizzoni A
    Lung Cancer; 2009 Aug; 65(2):251-3. PubMed ID: 19346026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of phase II trials of MTA in solid tumors.
    O'Dwyer PJ; Nelson K; Thornton DE
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):99-104. PubMed ID: 10598563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New developments in chemotherapy for advanced non-small cell lung cancer.
    Raez LE; Lilenbaum R
    Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.